Business Context and Reporting Period
This Form 6-K filing by Moolec Science SA (NASDAQ: MLEC) covers the month of March 2025, with the report dated March 14, 2025. The company is a public limited liability company governed by Luxembourg law, focused on biotechnology. The filing primarily addresses a critical regulatory matter regarding its listing status on The Nasdaq Stock Market.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and listing compliance issues rather than financial performance data.
Material Changes and Regulatory Status
- Nasdaq Non-Compliance: On March 11, 2025, Moolec received a Determination Letter from Nasdaq staff stating the company failed to regain compliance with Listing Rule 5550(a)(2) because its closing bid price remained below $1.00 per share for 30 consecutive business days as of September 10, 2024.
- Delisting Risk: The company is ineligible for a second 180-day compliance period due to failure to meet the $5,000,000 minimum stockholders' equity requirement. Without an appeal, delisting was scheduled for March 20, 2025.
- Appeal Filed: On March 13, 2025, the company appealed the determination to a Hearings Panel. This action automatically stays the delisting process pending the panel's decision.
- Proposed Remedy: The company intends to regain compliance by executing a reverse share split.
- Shareholder Action: On March 14, 2025, the Board of Directors resolved to convene an extraordinary shareholders meeting to vote on the reverse share split.
Outlook, Risks, and Management Commentary
Management is committed to implementing steps to comply with Nasdaq rules and is in close contact with Nasdaq staff. However, the filing explicitly states there is no assurance that the Hearings Panel will grant an extension period or that the company will meet necessary criteria within any granted extension. The document includes standard forward-looking statement disclaimers, noting that actual results may differ materially from projections due to risks such as regulatory changes, economic factors, and scaling costs.
Key Facts for Investor Verification
- Verify the outcome of the appeal to the Nasdaq Hearings Panel, as the delisting stay is temporary pending this decision.
- Confirm the date and results of the extraordinary shareholders meeting regarding the proposed reverse share split.
- Review the company's stockholders' equity to understand the ineligibility for a second compliance period.
- Monitor the stock price to ensure it meets the $1.00 threshold post-split if the remedy is approved.